gefitinib has been researched along with trimethoprim in 8 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (trimethoprim) | Trials (trimethoprim) | Recent Studies (post-2010) (trimethoprim) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 6,989 | 845 | 894 |
Protein | Taxonomy | gefitinib (IC50) | trimethoprim (IC50) |
---|---|---|---|
Chain A, Dihydrofolate reductase | Bacillus anthracis | 77200 | |
Chain A, dihydrofolate reductase (DHFR) | Bacillus anthracis | 77200 | |
Dihydrofolate reductase | Mycobacterium avium | 0.2588 | |
Dihydrofolate reductase | Homo sapiens (human) | 1.8206 | |
Dihydrofolate reductase | Lacticaseibacillus casei | 0.3493 | |
Dihydrofolate reductase type 1 | Escherichia coli | 0.25 | |
Dihydrofolate reductase | Neisseria gonorrhoeae | 0.45 | |
Thymidylate synthase | Homo sapiens (human) | 3.405 | |
Dihydrofolate reductase | Staphylococcus aureus | 0.0875 | |
Thymidylate synthase | Escherichia coli K-12 | 3.405 | |
Dihydrofolate reductase | Escherichia coli K-12 | 0.6064 | |
Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.01 | |
Dihydrofolate reductase type 1 from Tn4003 | Staphylococcus aureus | 0.023 | |
Dipeptidyl peptidase 4 | Rattus norvegicus (Norway rat) | 2.7 | |
Dihydrofolate reductase | Pneumocystis carinii | 0.7061 | |
Dihydrofolate reductase | Candida albicans | 0.1361 | |
Dipeptidyl peptidase 4 | Homo sapiens (human) | 2.7 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.45 | |
Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | 2.73 | |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 2.8 | |
Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 3.2206 | |
Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium berghei ANKA | 0.12 | |
Dihydrofolate reductase | Streptococcus pneumoniae TIGR4 | 0.0297 | |
Dihydrofolate reductase | Lactococcus lactis subsp. lactis Il1403 | 0.45 | |
Dihydrofolate reductase | Bacillus anthracis | 4.77 | |
Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 1.244 | |
Dihydrofolate reductase | Pneumocystis jirovecii | 0.092 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (37.50) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for gefitinib and trimethoprim
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for gefitinib and trimethoprim
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |